Delving into the Latest Updates on Fermagate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Alpharen, Macrosorb MD

Target

Phosphates

Action

modulators

Mechanism

Phosphates modulators(Phosphates modulators)

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

Hypophosphatemia

Inactive Indication

HyperphosphatemiaKidney Failure, Chronic

Originator Organization

Ineos Healthcare Ltd.

Active Organization

Prolor Biotech Ltd.

Inactive Organization

Ineos Healthcare Ltd.OPKO Renal LLC

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaCH20Fe2Mg4O19

InChIKeyVESOWWBEYMMDFG-UHFFFAOYSA-A

CAS Registry119175-48-3

Magnesium iron hydroxycarbonate is a phosphate binder that absorbs phosphate from food, reducing the amount that the body can absorb.
The purpose of this study is to assess the efficacy of magnesium iron hydroxycarbonate in subjects requiring haemodialysis, compared with a marketed phosphate binder, sevelamer hydrochloride.

Start Date01 Jul 2009

Sponsor / Collaborator

Ineos Healthcare Ltd.

NCT00436683

/ CompletedPhase 2

An Open Label, Dose-Ranging Study to Establish the Tolerability of Magnesium Iron Hydroxycarbonate in Haemodialysis Subjects With Hyperphosphataemia.

Magnesium iron hydroxycarbonate is a phosphate binder that absorbs phosphate from food, reducing the amount that the body can absorb.
The purpose of this study is to determine how well a range of different doses of fermagate are tolerated by the subjects in the trial.

Start Date01 Feb 2007

Sponsor / Collaborator

Ineos Healthcare Ltd.

EUCTR2006-004735-30-GB

/ Not yet recruitingPhase 2

An open label, dose-ranging study to establish the tolerability of Alpharen™ in haemodialysis subjects with hyperphosphataemia. - ACT 3

Start Date20 Nov 2006

Sponsor / Collaborator

Ineos Healthcare Ltd.

100 Clinical Results associated with Fermagate

Login to view more data

100 Translational Medicine associated with Fermagate

Login to view more data

100 Patents (Medical) associated with Fermagate

Login to view more data

14

Literatures (Medical) associated with Fermagate

01 Sep 2021·International urology and nephrologyQ4 · MEDICINE

Using iron-based phosphate binders in phosphate reduction and anemia improvement in patients receiving dialysis: a meta-analysis of randomized controlled trials

Q4 · MEDICINE

Article

Author: Zhu, Yan ; Li, Wei ; Xue, Chao ; Liao, Xueling ; Rao, Jinlan ; Ou, Jihong

PURPOSE:

A study was conducted to determine whether iron-based phosphate binders (IBPBs) need to be preferred for hyperphosphatemia and anemia management in patients on dialysis.

METHODS:

For this meta-analysis, we searched PubMed, Embase, and Cochrane Central Register of Controlled Trials for randomized controlled trials that evaluated the efficacy and safety of IBPBs in decreasing phosphate and correcting anemia in dialysis patients.

RESULTS:

Nineteen trials comprising 4719 participants were included. Compared with placebo, serum phosphate decreased significantly after treatment with ferric citrate (FC), fermagate (one study), and SBR759 (one study). Hemoglobin increased significantly after treatment with FC and sucroferric oxyhydroxide (PA21). In addition, FC and PA21 reduced serum intact parathyroid hormone (iPTH) and increased ferritin and transferrin saturation, but SBR759 did not. Compared with active treatment, the non-inferiority of IBPBs in reducing serum phosphate and iPTH was demonstrated. FC significantly improved serum hemoglobin and iron-related parameters and decreased the use of intravenous iron and erythropoiesis-stimulating agent, whereas PA21 did not increase serum hemoglobin level. The incidences of infection and hospitalization were similar between the two groups, with FC having a higher risk of diarrhea than the placebo and active treatments.

CONCLUSION:

FC was associated with the control of hyperphosphatemia and the improvement of anemia. However, PA21 did not show superiority for alleviating anemia compared with the active treatment. Other IBPBs, such as fermagate and SBR759, remained poorly understood due to the limited number of studies. Further trials are required to assess the effect of IBPBs on the risk of cardiovascular events and all-cause mortality.

23 Mar 2017·Journal of Physical Chemistry C

Carbonate–Hydrogenocarbonate Coexistence and Dynamics in Layered Double Hydroxides

Author: Carteret, Cédric ; Di Bitetto, Arnaud ; André, Erwan ; Durand, Pierrick ; Kervern, Gwendal

Carbonated layered double hydroxides were fully characterized by vibrational spectroscopies, powder x-ray diffraction and solid-state NMR tuning the cations, the layer charge d., and the preparation method to get original structural and dynamical features within the materials.It clearly appears that carbonate and hydrogenocarbonate coexist in the same interlayer after contact with air and also that the hydrogenocarbonate quantity is correlated to the M^II/M^III molar ratio constituting a strong pH probe of the interlayer space.Likewise, these two species are involved in an exchange process with atm. CO₂, and hydrogenocarbonate proves to be the key parameter of exchange kinetics.These crucial results, extended to various cationic couples, could lead to new alternatives for CO₂ storage.

02 Jan 2015·Renal failureQ4 · MEDICINE

Effects and safety of iron-based phosphate binders in dialysis patients: a systematic review and meta-analysis

Q4 · MEDICINE

ReviewOA

Author: Sun, Jing ; Zhai, Chun-Juan ; Wang, Rong ; Yu, Xin-Shuang ; Yang, Xiao-Wei

AIM:

To assess the effects and safety of iron-based phosphate binders in adult patients receiving dialysis.

METHODS:

We electronically searched MEDLINE, EMBASE, CENTRAL, and CBM for randomized controlled trials about iron-based phosphate binders in adult dialysis patients. Study quality was assessed using the criteria outlined in the Cochrane Handbook for Systematic Reviews of intervention. Meta-analysis was conducted by RevMan 5.3.

RESULTS:

Eight studies with 2018 participants were eligible for our meta-analysis. Iron-based phosphate binders were superior to placebo (MD = -2.43 mg/dL, 95% CI: -3.18 to -1.68, p < 0.00001) and as efficient as sevelamer (MD = 0.04 mg/dL, 95% CI: -0.29 to 0.36, p = 0.83) in reducing serum phosphorus in dialysis patients. No significant differences were found in all adverse events (OR = 1.30, 95% CI: 0.77 to 2.20, p = 0.32) between iron-based phosphate binders and placebo. Iron-based phosphate binders were associated with significant higher serum iron (MD = 9.39 ng/mL, 95% CI 1.48 to 17.30, p = 0.02), higher serum transferring saturation (MD = 6.29%, 95% CI 2.72 to 9.87, p = 0.0006) and lower serum total iron binding capacity (MD = -23.13 µg/dL, 95% CI -35.69 to -10.58, p = 0.0003) in comparison to placebo.

CONCLUSION:

Iron-based phosphate binders are as effective as sevelamer and well tolerated for hyperphosphatemia in dialysis patients. Iron-based phosphate binders appear to have a beneficial effect on renal anemia in patients receiving dialysis. Therefore, iron-based phosphate binders may represent a new treatment option for dialysis patients.

100 Deals associated with Fermagate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Fermagate	-	-

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hyperphosphatemia	Phase 3	United States	Ineos Healthcare Ltd.	01 Jul 2009
Hyperphosphatemia	Phase 3	Belgium	Ineos Healthcare Ltd.	01 Jul 2009
Hyperphosphatemia	Phase 3	Brazil	Ineos Healthcare Ltd.	01 Jul 2009
Hyperphosphatemia	Phase 3	Bulgaria	Ineos Healthcare Ltd.	01 Jul 2009
Hyperphosphatemia	Phase 3	Czechia	Ineos Healthcare Ltd.	01 Jul 2009
Hyperphosphatemia	Phase 3	Estonia	Ineos Healthcare Ltd.	01 Jul 2009
Hyperphosphatemia	Phase 3	Hungary	Ineos Healthcare Ltd.	01 Jul 2009
Hyperphosphatemia	Phase 3	Israel	Ineos Healthcare Ltd.	01 Jul 2009
Hyperphosphatemia	Phase 3	Italy	Ineos Healthcare Ltd.	01 Jul 2009
Hyperphosphatemia	Phase 3	Lithuania	Ineos Healthcare Ltd.	01 Jul 2009

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASN2018	Not Applicable	Chronic Kidney Diseases	23	Fermagate	lixowkjiaj(nyobuloowr) = tucbipxmtr gtwwvyetnn (bfsenlrgxa, 79%/65%inCONvs.35%FER(0.75%P)and13%FER(0.5-1%P) - p<0.001)	Positive	23 Oct 2018
ASN2012	Phase 3	-	-	Fermagate 1.5 g/d	taaohzgzha(wbsldvlufj) = 11.6% for F aywcbiuokc (hffzrvbkma ) View more	Positive	30 Oct 2012
ASN2012	Phase 3	-	-	Sevelamer HCl 2.4 g/d		Positive	30 Oct 2012